A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

July 27, 2023 updated by: Janssen Pharmaceutical K.K.

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis

The purpose of this study is to evaluate the efficacy of ustekinumab compared to placebo, in combination with oral glucocorticoid (GC) taper regimen, in participants with relapsing Takayasu Arteritis (TAK).

Study Overview

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bunkyo-Ku, Japan, 113-8519
        • Tokyo Medical and Dental University Hospital
      • Chiba, Japan, 260-8677
        • Chiba University Hospital
      • Fukuoka, Japan, 812-8582
        • Kyushu University Hospital
      • Hamamatsu, Japan, 431-3192
        • Hamamatsu University Hospital
      • Iruma-gun, Japan, 350-0495
        • Saitama Medical University Hospital
      • Kita-Gun, Japan, 761-0793
        • Kagawa University Hospital
      • Kobe, Japan, 650-0017
        • Kobe University Hospital
      • Kyoto, Japan, 606-8507
        • Kyoto University Hospital
      • Matsuyama-City, Japan, 790-8524
        • Matsuyama Red Cross Hospital
      • Nagoya-City, Japan, 467-8602
        • Nagoya City University Hospital
      • Niigata, Japan, 951-8520
        • Niigata University Medical & Dental Hospital
      • Okayama, Japan, 700-8558
        • Okayama University Hospital
      • Osaka, Japan, 530-8480
        • Kitano Hospital
      • Osaka, Japan, 598-8577
        • Rinku General Medical Center
      • Osaka-Sayama-shi, Japan, 589-8511
        • Kindai University Hospital
      • Sagamihara, Japan, 252-0375
        • Kitasato University Hospital
      • Sapporo, Japan, 060-8543
        • Sapporo Medical University Hospital
      • Sapporo-shi, Japan, 060-8648
        • Hokkaido University Hospital
      • Sendai, Japan, 980-8574
        • Tohoku University Hospital
      • Suita-Shi, Japan, 564-8565
        • National Cerebral and Cardiovascular Center
      • Tokyo, Japan, 104-8560
        • St. Luke's International Hospital
      • Tokyo, Japan, 162-8655
        • National Center for Global Health and Medicine
      • Tokyo, Japan, 101-8643
        • Mitsui Memorial Hospital
      • Toyoake, Japan, 470-1192
        • Fujita Health University Hospital
      • Tsukuba, Japan, 305-8576
        • University of Tsukuba Hospital
      • Wakayama, Japan, 641-8510
        • Wakayama Medical University Hospital
      • Yonago, Japan, 683-8504
        • Tottori University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 75 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Must have developed a relapse of Takayasu Arteritis (TAK) within 12 weeks prior to administration of study intervention and the relapse must have occurred at a dose of at least 7.5 milligrams (mg)/day (prednisolone or equivalent)
  • Must be receiving oral glucorticoid (GC) treatment of greater than or equal to (>=)15 mg/day (prednisolone or equivalent), inclusive for the treatment of relapsing TAK and be on a stable dose for at least 2 weeks prior to the first administration of study intervention
  • If receiving an oral anti-platelet therapy (including but not limited to aspirin, clopidogrel, ticlopidine) or anti-coagulation therapy (including but not limited to warfarin) for treatment of TAK, the dose must have been stable for at least 2 weeks prior to first administration of the study intervention. In terms of warfarin, the dose should be controlled 1-5mg/day to maintain Prothrombin Time and International Normalized Ratio (PT-INR) target range between 2.0-3.0 (if participants are over 70 years old, PT-INR target range should be between 1.6-2.6)
  • Have no history of latent or active Tuberculosis (TB) prior to screening. An exception is made for participants who have a history of latent TB and are currently receiving treatment for latent TB, will initiate treatment for latent TB at least 3 weeks prior to the first administration of the study intervention, or have documentation of having completed appropriate treatment for latent TB within 3 years prior to the first administration of the study intervention. It is the responsibility of the investigator to verify the adequacy of previous antituberculous treatment and provide appropriate documentation
  • If receiving an oral anti-hypertensive therapy for treatment of TAK, the dose must have been stable for at least 2 weeks prior to first administration of the study intervention

Exclusion Criteria:

  • Has currently any known severe or uncontrolled TAK complications (example, hypertension not responding to adequate treatment, aortic incompetence with cardiac insufficiency, progressing aortic aneurysm, coronary artery lesions with severe stenosis)
  • Has received immunosuppressant (s) (including but not limited to Methotrexate [MTX], Azathioprine [AZA], Mycophenolate Mofetil [MMF], oral Triamcinolone [TAC], oral Cyclosporine A) within 4 weeks of first study intervention
  • Has had a Bacille Calmette-guerin (BCG) vaccination within 12 months of screening
  • Any major illness/condition or evidence of an unstable clinical condition example, history of liver or renal insufficiency (estimated creatinine clearance below 60 milliliters/minute [mL/min]); significant (cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances), disease of any organ system or active acute or chronic infection/infectious illness that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study
  • Having a condition that is steroid dependent (example, steroid dependent asthma, chronic obstructive pulmonary disease, et cetera) that is not amenable to tapering oral GC

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ustekinumab

Double-blind (DB) Period: Participants will receive weight-ranged based ustekinumab (6 milligrams/kilogram[mg/kg]) as IV infusion at Week 0 followed by ustekinumab 90mg injection SC 8 weeks after initial IV dose, then every 8 weeks (q8w) thereafter until the end of the DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.

Open Label Extension (OLE) period: Participants will receive ustekinumab SC injection at Week OL-0, followed by ustekinumab 90mg SC injection with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from first SC administration after end of DB period whichever is later.

Long-term Extension (LTE) Period: Participants who completed OLE period may be eligible to enter LTE and continue to receive ustekinumab 90mg SC injection q8w.

Participants will receive IV infusion and SC injection of ustekinumab.
Other Names:
  • Stelara®
  • CNTO1275
Glucocorticoid will be administered orally.
Placebo Comparator: Placebo

DB period: Participants will receive placebo intravenous (IV) infusion at Week 0 followed by placebo subcutaneous (SC) injection administration, 8 weeks after the initial IV dose, then q8w thereafter until the end of DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.

OLE period: Participants will receive ustekinumab SC at Week OL-0, followed by SC administration of ustekinumab with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from the first SC administration after the end of DB period, whichever is later.

LTE Period: Participants who complete their participation in OLE period may be eligible to enter the LTE and continue to receive 90 mg SC ustekinumab q8w.

Participants will receive IV infusion and SC injection of ustekinumab.
Other Names:
  • Stelara®
  • CNTO1275
Glucocorticoid will be administered orally.
Participants will receive IV infusion and SC injection of matching placebo.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Relapse Through the End of Double-blind (DB) Period
Time Frame: Up to occurrence of 35 events (Up to 24 months)
Time to relapse is defined as the assessment of 'signs of relapse present' as judged by the investigator for at least 2 of 5 categories: objective systemic symptoms, subjective systemic symptoms, elevated inflammation markers, vascular signs and symptoms, or ischemic symptoms.
Up to occurrence of 35 events (Up to 24 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Time Frame: Up to 3 years
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
Up to 3 years
Number of Participants with TEAEs by System Organ Class (SOC) with a Frequency Threshold of 5 Percent (%) or More
Time Frame: Up to 3 years
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
Up to 3 years
Number of Participants with Treatment-emergent Serious Adverse Events (SAEs)
Time Frame: Up to 3 years
SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. Treatment-emergent SAEs are defined as SAEs with onset or worsening on or after date of first dose of study treatment.
Up to 3 years
Time to Relapse of TAK by Kerr's Criteria Through the End of DB Period
Time Frame: Up to occurrence of 35 events (Up to 24 months)
Time to relapse is defined as the assessment of 'signs of relapse present as judged by the investigator for at least 2 of 4 categories: systemic symptoms (objective or subjective), elevated inflammation markers, vascular signs, and symptoms and ischemic symptoms.
Up to occurrence of 35 events (Up to 24 months)
Time to Relapse Based on Clinical Symptoms Through the End of DB Period
Time Frame: Up to occurrence of 35 events (Up to 24 months)
Time to relapse based on clinical symptoms through the end of DB period will be reported. Participants who meet at least 1 category in the following 4 clinical categories will be considered as relapse per clinical symptom: 1) Objective systemic symptoms; 2) Subjective systemic symptoms; 3) Vascular signs and symptoms; 4) Ischemic symptoms.
Up to occurrence of 35 events (Up to 24 months)
Time to Relapse of TAK in Each of the 5 Categories Through the End of DB Period
Time Frame: Up to occurrence of 35 events (Up to 24 months)
Time to relapse is defined as the assessment of 'signs of relapse present' as judged by the investigator in each of the 5 categories: objective systemic symptoms, subjective systemic symptoms, elevated inflammation markers, vascular signs and symptoms, or ischemic symptoms.
Up to occurrence of 35 events (Up to 24 months)
Percentage of Participants with Relapse in Each of the 5 Categories Through the End of DB Period
Time Frame: Up to occurrence of 35 events (Up to 24 months)
Percentage of participants with relapse in each of the 5 categories (objective systemic symptoms, subjective systemic symptoms, elevated inflammation markers, vascular signs and symptoms, or ischemic symptoms) through the end of DB period will be reported.
Up to occurrence of 35 events (Up to 24 months)
Cumulative Oral Glucocorticoid (GC) Dose Through the End of DB Period
Time Frame: Up to occurrence of 35 events (Up to 24 months)
Cumulative oral GC dose (prednisolone or equivalent) through the end of DB period will be reported.
Up to occurrence of 35 events (Up to 24 months)
Change from Baseline in Oral GC Dose Through the End of DB Period
Time Frame: Baseline; up to the end of DB period (Up to 24 months)
Change from baseline in oral GC dose (prednisolone or equivalent) through the end of DB period will be reported.
Baseline; up to the end of DB period (Up to 24 months)
Number of Participants Achieving GC Dose of 5 milligrams (mg)/day or Less Through the End of DB Period
Time Frame: Up to 24 months
Number of participants achieving GC dose of 5 mg/day or less at the end of DB period will be reported.
Up to 24 months
Number of Participants with Change from Baseline in Imaging Evaluation Through the End of DB Period
Time Frame: Baseline, every 24 weeks from Week 0 and relapse confirmation visit (Up to 24 months)
Number of participants with change from baseline in imaging evaluation through the end of DB period will be reported. Vessel involvement such as stenosis, obstruction, and aneurysm; arterial wall thickness; and the presence of mural contrast enhancement and oedema will be assessed for imaging evaluation using magnetic resonance angiography (MRA).
Baseline, every 24 weeks from Week 0 and relapse confirmation visit (Up to 24 months)
Change from Baseline in C-reactive Protein (CRP) Through the End of DB Period
Time Frame: Baseline; up to 24 months
Change from baseline in CRP through the end of DB period will be reported.
Baseline; up to 24 months
Change from Baseline in Erythrocyte Sedimentation Rate (ESR) Through the End of DB Period
Time Frame: Baseline; up to 24 months
Change from baseline in ESR through the end of DB period will be reported.
Baseline; up to 24 months
Serum Concentrations of Ustekinumab
Time Frame: Up to end of study (Up to 3 years)
Serum concentrations of ustekinumab will be reported.
Up to end of study (Up to 3 years)
Number of Participants with Positive Anti-ustekinumab Antibodies
Time Frame: Up to end of study (Up to 3 years)
Number of participants with positive anti-ustekinumab antibodies will be reported.
Up to end of study (Up to 3 years)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Janssen Pharmaceutical K.K., Japan Clinical Trial, Janssen Pharmaceutical K.K.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 15, 2021

Primary Completion (Actual)

May 25, 2023

Study Completion (Actual)

May 25, 2023

Study Registration Dates

First Submitted

May 10, 2021

First Submitted That Met QC Criteria

May 10, 2021

First Posted (Actual)

May 11, 2021

Study Record Updates

Last Update Posted (Actual)

August 1, 2023

Last Update Submitted That Met QC Criteria

July 27, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • CR108981
  • CNTO1275TAT3001 (Other Identifier: Janssen Pharmaceutical K.K., Japan)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Takayasu Arteritis

Clinical Trials on Ustekinumab

3
Subscribe